Financial reports
20-F
2022 FY
Annual report (foreign)
1 May 23
20-F/A
2021 FY
Annual report (foreign) (amended)
12 Sep 22
20-F
2021 FY
Annual report (foreign)
28 Jun 22
NT 20-F
Notice of late annual filing (foreign)
3 May 22
20-F
2020 FY
Annual report (foreign)
17 May 21
NT 20-F
Notice of late annual filing (foreign)
3 May 21
20-F/A
2019 FY
Annual report (foreign) (amended)
31 Mar 21
20-F
2019 FY
Annual report (foreign)
5 Aug 20
20-F
2018 FY
Annual report (foreign)
30 Apr 19
20-F
2017 FY
Annual report (foreign)
11 May 18
Current reports
6-K
RepliCel announces a Letter of Intent for Asset Purchase Agreement
20 Mar 24
6-K
Condensed Consolidated Interim Financial Statements
30 Nov 23
6-K
Condensed Consolidated Interim Financial Statements
24 Oct 23
6-K
Current report (foreign)
19 Oct 23
6-K
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
4 Oct 23
6-K
RepliCel Announces DermaPreciseā¢ Development Milestone, Updates Arbitration Proceedings
13 Sep 23
6-K
Current report (foreign)
7 Sep 23
6-K
Notice of Annual General and Special Meeting of Shareholders
30 Aug 23
6-K
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
29 Aug 23
6-K
Annual General and Special Meeting
17 Aug 23
Registration and prospectus
D
$740.78 k in equity / options / securities to be acquired, sold $740.78 k, 5 investors
16 Mar 23
D
$9.20 k in equity, sold $9.20 k, 1 investor
7 Feb 23
D
$86.94 k in equity, sold $86.94 k, 2 investors
25 Jan 23
D
$558.84 k in equity / options / securities to be acquired, sold $558.84 k, 2 investors
5 Jan 23
D
$592.73K in equity / options / securities to be acquired, sold $592.73K, 2 investors
10 May 22
D
$777.66K in equity, sold $777.66K, 1 investor
20 Dec 21
D/A
$161.52K in equity, sold $161.52K, 3 investors
14 Jun 21
D
$111.57K in equity, sold $111.57K, 2 investors
3 Jun 21
D
$9.01K in equity, sold $9.01K, 1 investor
27 May 21
D
$385.85K in equity, sold $385.85K, 1 investor
26 Feb 21
Other
UPLOAD
Letter from SEC
20 Sep 22
UPLOAD
Letter from SEC
23 Aug 22
UPLOAD
Letter from SEC
18 Jan 18
CORRESP
Correspondence with SEC
12 Jan 18
UPLOAD
Letter from SEC
13 Dec 17
UPLOAD
Letter from SEC
29 Jun 15
CORRESP
Correspondence with SEC
28 May 15
CORRESP
Correspondence with SEC
19 May 15
UPLOAD
Letter from SEC
7 May 15
CORRESP
Correspondence with SEC
16 Apr 15
Ownership
SC 13D/A
Schutte Andrew
20 Apr 23
SC 13D/A
Schutte Andrew
26 Jan 23
SC 13D/A
MACKAY JAMIE MYLES
5 Jan 23
SC 13D
MACKAY JAMIE MYLES
29 Sep 22
SC 13D/A
Schutte Andrew
2 Jun 22
SC 13D/A
MAINPOINTE PHARMACEUTICALS, LLC
21 Dec 21
SC 13D
MAINPOINTE PHARMACEUTICALS, LLC
4 Jun 21
SC 13D/A
Schutte Andrew
17 Sep 20
SC 13D
Replicel Life Sciences Inc.
12 Sep 18